Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Cancer Res. 2021 Nov 4;82(1):169–176. doi: 10.1158/0008-5472.CAN-21-1467

Fig. 4. Recurrent copy number variations associated with neoadjuvant chemotherapy.

Fig. 4.

(A) The frequency of CNVs in the patient cohort captures recurrent CNVs observed in the TCGA analysis of HGSOC such as amplification of 3q and 8q and deletion of chromosomes 16 and 22. (B) Comparing TCGA HGSOC cohort normalized SIK2 mRNA expression to copy number alteration data reveals increased SIK2 expression with copy number gain or amplification. (C) GISTIC2.0 analysis of differentially amplified (red) and deleted (blue) regions identifies recurrent CNVs present both pre- and post-NACT, including frequent amplification of SIK2 in 11q23.1 which contains 75 total genes (Table S14). Chromosome locations are indicated on the x-axis. (D) Treatment of OVCAR8 cells with a combination of paclitaxel (PTX, 100 nM) or carboplatin (CP, 100 μM) and a SIK2 inhibitor (HG-9-91-01; 5 μM) leads to synergistic cytotoxicity based on 2-way ANOVA and Tukey’s test. Proliferation data demonstrating percent change in the Hoechst positive area between the 24 and 48 hour post treatment time points is shown in the panels on the right ***ANOVA p < 0.001. Supplementary Figures